Drugs / REGN7257
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04409080 | Jan 2021 → Oct 2024 | aplastic anemia | Regeneron Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-11-03 | Regeneron Pharmaceuticals | Results Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH regeneron.com ↗
Blockade of Common Gamma Chain Cytokine Signaling with REGN7257, an Interleukin 2 Receptor Gamma (IL2RG) Monoclonal Antibody, in Combination with Costimulatory Blockers Delayed Skin Graft Rejection in Mice |
| 2022-11-03 | Regeneron Pharmaceuticals | Results Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders regeneron.com ↗
Blockade of common gamma chain cytokine signaling with REGN7257, an interleukin 2 receptor gamma (IL2RG) monoclonal antibody, protected mice from inflammatory and autoimmune diseases |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-03 | Regeneron Pharmaceuticals | Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH regeneron.com ↗ |
| 2022-11-03 | Regeneron Pharmaceuticals | Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders regeneron.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN7257 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04409080 ↗ |
| Action | Inhibit | “Anti-Interleukin 2 Receptor Subunit Gamma” NCT04409080 ↗ |
| Modality | Monoclonal antibody | “IL2RG] Monoclonal Antibody” NCT04409080 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion” NCT04409080 ↗ |